Sagimet Biosciences Inc. (SGMT)
Pre-Market:
| Previous Close | 4.7000 |
| Open | 4.7200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 4.6000 - 4.9100 |
| 52 Week Range | 2.1300 - 20.7100 |
| Volume | |
| Avg. Volume | 700,188 |
| Market Cap | 153.825M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.20 |
GlobeNewswireSagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet’s topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASHSAN MATEO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual investor and analyst day on Thursday, May 23
- GlobeNewswire
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Denifanstat Phase 2b FASCINATE-2 clinical data to be presented as an oral presentation at the EASL International Liver Congress 2024 taking place in Milan, Italy from June 5-8, 2024 End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) expected in the second quarter of 2024 Preparations are underway to start a pivotal Phase 3 trial evaluating denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Anticipated cash runway throu
- GlobeNewswire
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
SAN MATEO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced a General Session oral presentation of denifanstat Phase 2b FASCINATE-2 study data in metabolic dysfunction-associated steatohepatitis (MASH) will be given at the European Association for the Study of the Liver (EASL)
